Actively Recruiting
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer
Led by Centre Georges Francois Leclerc · Updated on 2026-04-03
613
Participants Needed
6
Research Sites
443 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.
CONDITIONS
Official Title
EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Major or minor patient
- Histological or cytological evidence of malignant tumor diagnosis
- Patient with cancer before age 40 (or before age 30 for breast cancer)
- No anomaly found on the oncogenetic panel tested in the predisposition concerned
- Patient affiliated to a social security scheme
- Signed informed consent for EXTRICAN study
- Availability of a tumor sample if needed for secondary functional studies
- Availability of both parents when trio approach is necessary (or validation if not available)
- Availability of affected relatives when needed (or validation if not available)
- Related patients must be major or minor
- Histological or cytological evidence of malignant tumor diagnosis for related patients
- Related patients affiliated to a social security scheme
- Related patients signed informed consent for EXTRICAN study
You will not qualify if you...
- Refusal to participate in the study
- Psychiatric illness or condition impairing understanding or ability to participate
- Under guardianship, curatorship, or safeguard of justice
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
CHRU Jean Minjoz
Besançon, France
Not Yet Recruiting
2
Centre Georges-François Leclerc
Dijon, France, 21000
Actively Recruiting
3
CHU de Dijon
Dijon, France
Not Yet Recruiting
4
CHU de Reims
Reims, France
Not Yet Recruiting
5
Polyclinique de Courlancy
Reims, France
Not Yet Recruiting
6
CH de Troyes
Troyes, France
Not Yet Recruiting
Research Team
S
Sophie NAMBOT, Dr
CONTACT
E
Emilie REDERSTORFF
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here